Surgery plus maintenance medicines for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and your cancer is confirmed as epithelial ovarian cancer (or fallopian tube or primary peritoneal cancer).
- Your cancer is stage IIIC or IV, and scans show a “low to high” tumor burden but a specific cPCI score of 12 or less.
- Doctors believe they can remove all visible tumor during surgery (complete cytoreduction) based on scan results.
- You agree to genetic/genome testing for BRCA and HRD before starting treatment.
- Your general condition is good enough for treatment (ECOG 0–2), and your blood, kidney, and liver labs are within required limits.
- You must be able to start and complete chemotherapy and the planned follow-up visits, and you must sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks if adjusting the timing of surgery (interval debulking surgery) after chemotherapy can improve outcomes for people with advanced ovarian cancer. It's for those who cannot have surgery right away and will receive chemotherapy first.
This trial tests combining surgery with an immunotherapy drug (sintilimab) for women whose ovarian cancer has returned after initial treatment. It aims to see if this approach can improve outcomes for people with specific tumor markers.
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
This Phase 3 trial tests whether patients with advanced ovarian, fallopian tube, or primary peritoneal cancer do better with surgery first versus chemotherapy first. It also groups people based on how extensive the cancer is to choose the best approach.
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy before surgery for advanced ovarian cancer. The goal is to see if this treatment shrinks the cancer more and makes surgery more effective.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.